
Mesenchymal stem cells
Apceth, a leader in the development of stem cell treatments, has won approval for a Phase I/II multicenter clinical trial evaluating an autologous mesenchymal stem cell (MSC) therapy for gastrointestinal cancer. The treatment involves the utilization of the patient’s own stem cells to combat and destroy cancerous cells and is designed to enable highly localized treatments.